HCPLive Network
PERSONAL FINANCE

Celgene Sell Off “Overdone”

Laura Joszt | Friday, June 22, 2012
While Onyx Pharmaceuticals is flying high on good news for its blood cancer drug, Celgene wasn’t quite so lucky. Celgene’s stock took a big hit on Thursday when it withdrew its application for Revlimid. And by the end of the week, the stock hadn’t recovered much.
 
When the European Medicine’s Agency (EMA) indicated it wanted more data on Revlimid’s application to be used on newly diagnosed multiple myeloma patients and as a maintenance therapy, Celgene withdrew the application. When news broke, its stock dropped 11.65% at the opening bell on Thursday.
 
By the end of the day Friday, the stock had only recovered slightly, up 3.68%, but still down by 8.19% over where it had closed on Wednesday afternoon.
 
 
However, investors might be a little trigger happy with Celgene. For one, the company could still resubmit to EMA. Also, a trial combining Onyx’s Kyprolis with Revlimid and Dexa revealed that patients had a 98% response rate and a 92% progression-free survival rate.
 
Revlimid is already an approved blood cancer drug — the company is simply looking to expand its use. Plus, the drug could also have a number of other uses, such as lymphoma and CLL. Another Celgene drug could be approved for a second use this year.
 
According to SeekingAlpha, the sell off could nicely benefit investors who take advantage of it to buy up shares. Robert W. Baird released a note that it believed the sell off was overdone. The wealth management company has set a price target at $78.
 
The information contained in this article should not be construed as investment advice or as a solicitation to buy or sell any stock.
 
Read more:


RELATED ARTICLES
Many investors are still shy from the drubbing they took in 2008 or feel that it's too late to get into the market now. That kind of scared thinking is going to cost them.
The 401(k) retirement accounts of many employees are going up in smoke due to excessive fees charged by their investment company. Unless this can be rectified through legislation, higher earners may end up paying for the shortfall later.
When it comes to our finances, few of us are nearly as diligent as we are with our physical health. Most of us don’t keep good records, make budgets or monitor our overall financial health.
RECENT CLINICAL ARTICLES
Review by a German commission also found major benefits in patients who had not responded to prior treatment with other medications.
Physicians are often tasked with explaining vaccination safety to concerned parents. Parental fears that routine vaccines can trigger neurological diseases have led to decreasing vaccination rates in some countries and subsequent outbreaks of preventable illnesses. A team of Dutch researchers has debunked the idea that vaccination can cause severe epilepsy
US heart experts recommend doctors use a 14-point checklist rather than an electrocardiogram when evaluating young people for underlying heart disease that could result in sudden cardiac arrest.